bioRxiv preprint doi: https://doi.org/10.1101/2020.04.29.067983; this version posted April 30, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.

Evaluation of 19 antiviral drugs against SARS-CoV-2 Infection

Shufeng Liu[1], Christopher Z. Lien[1], Prabhuanand Selvaraj[1], Tony T. Wang[1,*]

[1]Laboratory of Vector-Borne Viral Diseases, Division of Viral Products, Center for Biologics Evaluation, U.S. Food and Drug Administration, Silver Spring, Maryland, United States of America.

*e-mail: Tony.Wang@fda.hhs.gov

Running Title: Remdesivir inhibits SARS-CoV-2

Abstract

The global pandemic of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 or 2019-nCoV) has prompted multiple clinical trials to jumpstart search for anti-SARS-CoV-2 therapies from existing drugs, including those with reported *in vitro* efficacies as well as those ones that are not known to inhibit SARS-CoV-2, such as ritonavir/lopinavir and favilavir. Here we report that after screening 19 antiviral drugs that are either in clinical trials or with proposed activity against SARS-CoV-2, remdesivir was the most effective. Chloroquine only effectively protected virus-induced cytopathic effect at around 30 µM with a therapeutic index of 1.5. Our findings also suggest that velpatasvir, ledipasvir, ritonavir, litonavir, lopinavir, favilavir, sofosbuvir, danoprevir, and pocapavir do not have direct antiviral effect.

bioRxiv preprint doi: https://doi.org/10.1101/2020.04.29.067983; this version posted April 30, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.

Main Text

The recently emerged SARS-CoV-2 is a novel coronavirus originated in Wuhan, China (Zhou et al., 2020) and causes coronavirus infectious disease 2019 (COVID-19), a new disease marked by fevers and pneumonia-like symptoms. As of date, SARS-CoV-2 has spread to essentially all continents and killed over 165,000 worldwide. The World Health Organization (WHO) has declared the SARS-CoV-2 outbreak a global pandemic. Unprecedented public-health measures including lockdown of major cities appear to have contained the spread of the virus within China, but the effectiveness of such measures at a global scale remains a contentious topic. Given a prophylactic vaccine will not likely be available in the immediate future, an effective therapeutic intervention could potentially be a game-changer in combating COVID-19. For this reason, multiple countries have unleashed a frenzy of clinical trials hoping to find a drug that can be repurposed to treat COVID-19. Nonetheless, there has been a paucity of information as to the direct antiviral effect of some drugs in trials. Here, we set out an *in vitro* study to evaluate 19 investigational antiviral drugs, including some approved by the FDA for other indications, for their efficacies against SARS-CoV-2. The list includes several viral RNA-dependent RNA polymerase (RdRP) inhibitors, viral protease inhibitors, chloroquine, a furin inhibitor, and a tyrosine kinase inhibitor. The rationale of choosing these drugs was based on *in silico* prediction(Elfiky, 2020), reported possible effect(Liu et al., 2020), and publicly reported trials(Cao et al., 2020). For example, Sofosbuvir, sold under the brand name Sovaldi among others, attracted our attention as a potent, once-daily, orally administered nucleotide analog prodrug inhibitor of the hepatitis C virus (HCV) NS5B polymerase. Sofosbuvir is metabolized *in vivo* to the active antiviral agent GS-461203 (2'-deoxy-2'-α-fluoro-β-C-methyluridine-5'-triphosphate). GS-461203 serves as a defective substrate for the NS5B protein, thus blocks viral RNA synthesis. Sofosbuvir has been identified in molecular docking as a potential SARS-CoV-2 inhibitor(Elfiky, 2020). Favilavir, an approved influenza RdRP inhibitor in China and Japan, is being used in a clinical trial in China to treat COVID-19(Liu et al., 2020). Several HCV or HIV protease inhibitors, such as Velpatasvir(Chen et al., 2020), Ledipasvir(Chen et al., 2020), Ritonavir(Shah et al., 2020), Lopinavir(Shah et al., 2020) are predicted to be possible anti-SARS-CoV-2 drugs as well.

Our screen assay is based on the protection of SARS-CoV-2-induced cytopathic effect (CPE), which is particularly pronounced in Vero cells. We hypothesized that inhibitors of virus infection would prevent cell death. One major advantage of the CPE-based screen is that compounds that are toxic to cells at the tested doses are simultaneously excluded for future consideration as a drug. To ensure our assay is robust, we carried out the screen under two different infectious doses (multiplicity of infection of 0.01 and 0.001, respectively). For most drugs, we tested three concentrations: 1, 10, 50 μM. When a drug displayed protective effect, we further expanded the range of concentrations to locate the half maximal inhibitory concentration (IC_{50}). The results are summarized in Table 1. Briefly, most drugs that we tested failed to prevent SARS-CoV-2-induced cell death, including Sofosbuvir and Favilavir. Additionally, combination of sofosbuvir and velpatasvir or ledipasvir failed to protect infected cells either. Chloroquine, as well as its hydroxyl form, had been allowed by the U.S. FDA to be provided to certain hospitalized patients under an emergency use authorization. In our study, however, chloroquine only showed minimal activity with an IC_{50} close to 30 μM when being added one hour prior to infection with a therapeutic index of 1.5. This finding contrasts with a reported IC_{50} of 6.9 μM in another study(Wang et al., 2020). Given that it normally takes more drug to achieve a full protection in a CPE-based assay, the IC_{50} measured by our assay is expected to be higher than that measured by assays measuring viral RNA(Wang et al., 2020). Nonetheless, when being added post-infection, chloroquine displayed negligible

bioRxiv preprint doi: https://doi.org/10.1101/2020.04.29.067983; this version posted April 30, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.

protective effect against virus-induced cell death. Altogether, our finding cautions conducting clinical trials with existing drugs in treating COVID-19. Without even *in vitro* efficacy support, using these drugs in patients is risky because potential side effects. Indeed, ritonavir and lopinavir were declared ineffective after a failed clinical trial(Cao et al., 2020); Brazilian government recently halted a small trial involving chloroquine after patients developed irregular heart rates. Our results did support the potential of Remdesivir as a drug to treat COVID-19. Remdesivir (GS-5734) is a nucleotide prodrug that has broad antiviral activity against viruses from different families in vitro(Lo et al., 2017), and therapeutic efficacy in nonhuman primate models of lethal Ebola virus and Nipah virus infection(Lo et al., 2019; Warren et al., 2016). Remdesivir (GS-5734) effectively inhibited MERS coronavirus (MERS-CoV) replication in vitro and showed efficacy against Severe Acute Respiratory Syndrome (SARS)-CoV in a mouse model(Sheahan et al., 2017). In consistent, compassionate use of remdesivir in patients hospitalized for severe COVID-19 displayed clinical improvement in 68% of the patients (68%)(J. Grein, 2020). Overall, our study reinforces the notion that clinical trials must be supported by rigorous pre-clinical studies as we take an accelerated pace of developing new drugs to combat SARS-CoV-2.

Methods

Drugs, Cells and Virus

Remdesivir, sofosbuvir, danoprevir, pocapavir, bemcentinib (R428) were purchased from Medchemexpress LLC. Chloroquine, velpatasvir, ledipasvir were bought from Fisher. Nelfinavir, ritonavir, saquinavir, indinavir, amprenavir, lopinavir, raltegravir, tenofovir, AZT were from NIH AIDS Reagent Program. Favilavir was obtained from Cayman Chemical and chloromethylketone was from Enzo Life Sciences.

Vero E6 cell line was purchased from American Type and Cell Collection (ATCC) and cultured in eagle's minimal essential medium (MEM) supplemented with 10% fetal bovine serum (Invitrogen) and 1% penicillin/streptomycin and L-glutamine.

The SARS-CoV-2 strain WA1-2020 was obtained from BEI Resources, NIAID, NIH, and had been passed three times on Vero cells and 1 time on Vero E6 cells prior to acquisition. It was further passed once on Vero E6 cells in our lab.

Virus titration

SARS-CoV-2 strain WA1-2020 was titered using the Reed & Muench Tissue Culture Infectious Dose 50 Assay (TCID50/ml) system (Reed, 1938). Vero cells were plated the day before infection into 96 well plates at 1.5 x 10^4 cells/well. On the day of the experiment, serial dilutions of virus were made in media and a total of 6-8 wells were infected with each serial dilution of the virus. After 48 hours incubation, cells were fixed in 4% paraformaldehyde followed by staining with 0.1% crystal violet. The TCID50 was then calculated using the formula: log (TCID50)=log(do)+ log (R)(f+1). Where do represents the dilution giving a positive well, f is a number derived from the number of positive wells calculated by a moving average, and R is the dilution factor.

bioRxiv preprint doi: https://doi.org/10.1101/2020.04.29.067983; this version posted April 30, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.

CPE-based drug screening assay.

VeroE6 cells were seeded at 1.8 x10^4cells/well in a 96 well plate 24 hours before the experiment. After cells had reached 80% confluency, they were infected with SARS-CoV-2 in the presence or absence of a compound for two hours. One hour (or whatever time it is) after the infection the virus was removed, and fresh compound was added back to each well. Two Days after infection media was removed from the cells and at least 50µl of the CellTiter-Glo® Reagent was then quickly added to all wells in the luminometer plate and the luciferase reading was quantified with a Veritas luminometer (Promega). The cytopathic effect was quantified by the CellTiter-Glo Luminescent Cell Viability Assay system (Promega, WI). Both IC_{50} and CC_{50} were calculated using Prism 7.0 (Graphpad).

References

Cao, B., Wang, Y., Wen, D., Liu, W., Wang, J., Fan, G., Ruan, L., Song, B., Cai, Y., Wei, M., Li, X., Xia, J., Chen, N., Xiang, J., Yu, T., Bai, T., Xie, X., Zhang, L., Li, C., Yuan, Y., Chen, H., Li, H., Huang, H., Tu, S., Gong, F., Liu, Y., Wei, Y., Dong, C., Zhou, F., Gu, X., Xu, J., Liu, Z., Zhang, Y., Li, H., Shang, L., Wang, K., Li, K., Zhou, X., Dong, X., Qu, Z., Lu, S., Hu, X., Ruan, S., Luo, S., Wu, J., Peng, L., Cheng, F., Pan, L., Zou, J., Jia, C., Wang, J., Liu, X., Wang, S., Wu, X., Ge, Q., He, J., Zhan, H., Qiu, F., Guo, L., Huang, C., Jaki, T., Hayden, F.G., Horby, P.W., Zhang, D., Wang, C., 2020. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med.

Chen, Y.W., Yiu, C.B., Wong, K.Y., 2020. Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CL (pro)) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates. F1000Res 9, 129.

Elfiky, A.A., 2020. Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study. Life Sci, 117592.

J. Grein, N.O., D. Shin, G. Diaz, E. Asperges, A. Castagna, T. Feldt, G. Green, M.L. Green, F.-X. Lescure, E. Nicastri, R. Oda, K. Yo, E. Quiros-Roldan, A. Studemeister, J. Redinski, S. Ahmed, J. Bernett, D. Chelliah, D. Chen, S. Chihara, S.H. Cohen, J. Cunningham, A. D'Arminio Monforte, S. Ismail, H. Kato, G. Lapadula, E. L'Her, T. Maeno, S. Majumder, M. Massari, M. Mora-Rillo, Y. Mutoh, D. Nguyen, E. Verweij, A. Zoufaly, A.O. Osinusi, A. DeZure, Y. Zhao, L. Zhong, A. Chokkalingam, E. Elboudwarej, L. Telep, L. Timbs, I. Henne, S. Sellers, H. Cao, S.K. Tan, L. Winterbourne, P. Desai, R. Mera, A. Gaggar, R.P. Myers, D.M. Brainard, R. Childs, and T. Flanigan 2020. Compassionate Use of Remdesivir for Patients with Severe Covid-19. The New England Journal of Medicine.

Liu, C., Zhou, Q., Li, Y., Garner, L.V., Watkins, S.P., Carter, L.J., Smoot, J., Gregg, A.C., Daniels, A.D., Jervey, S., Albaiu, D., 2020. Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases. ACS Cent Sci 6, 315-331.

Lo, M.K., Feldmann, F., Gary, J.M., Jordan, R., Bannister, R., Cronin, J., Patel, N.R., Klena, J.D., Nichol, S.T., Cihlar, T., Zaki, S.R., Feldmann, H., Spiropoulou, C.F., de Wit, E., 2019. Remdesivir (GS-5734) protects African green monkeys from Nipah virus challenge. Sci Transl Med 11.

Lo, M.K., Jordan, R., Arvey, A., Sudhamsu, J., Shrivastava-Ranjan, P., Hotard, A.L., Flint, M., McMullan, L.K., Siegel, D., Clarke, M.O., Mackman, R.L., Hui, H.C., Perron, M., Ray, A.S., Cihlar, T., Nichol, S.T., Spiropoulou, C.F., 2017. GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses. Sci Rep 7, 43395.

Reed, L.J., and H. Muench., 1938. A simple method for estimating fifty percent endpoints. Am. J. Hyg 27, 493-497.

Shah, B., Modi, P., Sagar, S.R., 2020. In silico studies on therapeutic agents for COVID-19: Drug repurposing approach. Life Sci, 117652.

bioRxiv preprint doi: https://doi.org/10.1101/2020.04.29.067983; this version posted April 30, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.

Sheahan, T.P., Sims, A.C., Graham, R.L., Menachery, V.D., Gralinski, L.E., Case, J.B., Leist, S.R., Pyrc, K., Feng, J.Y., Trantcheva, I., Bannister, R., Park, Y., Babusis, D., Clarke, M.O., Mackman, R.L., Spahn, J.E., Palmiotti, C.A., Siegel, D., Ray, A.S., Cihlar, T., Jordan, R., Denison, M.R., Baric, R.S., 2017. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med 9.

Wang, M., Cao, R., Zhang, L., Yang, X., Liu, J., Xu, M., Shi, Z., Hu, Z., Zhong, W., Xiao, G., 2020. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 30, 269-271.

Warren, T.K., Jordan, R., Lo, M.K., Ray, A.S., Mackman, R.L., Soloveva, V., Siegel, D., Perron, M., Bannister, R., Hui, H.C., Larson, N., Strickley, R., Wells, J., Stuthman, K.S., Van Tongeren, S.A., Garza, N.L., Donnelly, G., Shurtleff, A.C., Retterer, C.J., Gharaibeh, D., Zamani, R., Kenny, T., Eaton, B.P., Grimes, E., Welch, L.S., Gomba, L., Wilhelmsen, C.L., Nichols, D.K., Nuss, J.E., Nagle, E.R., Kugelman, J.R., Palacios, G., Doerffler, E., Neville, S., Carra, E., Clarke, M.O., Zhang, L., Lew, W., Ross, B., Wang, Q., Chun, K., Wolfe, L., Babusis, D., Park, Y., Stray, K.M., Trancheva, I., Feng, J.Y., Barauskas, O., Xu, Y., Wong, P., Braun, M.R., Flint, M., McMullan, L.K., Chen, S.S., Fearns, R., Swaminathan, S., Mayers, D.L., Spiropoulou, C.F., Lee, W.A., Nichol, S.T., Cihlar, T., Bavari, S., 2016. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature 531, 381-385.

Zhou, P., Yang, X.L., Wang, X.G., Hu, B., Zhang, L., Zhang, W., Si, H.R., Zhu, Y., Li, B., Huang, C.L., Chen, H.D., Chen, J., Luo, Y., Guo, H., Jiang, R.D., Liu, M.Q., Chen, Y., Shen, X.R., Wang, X., Zheng, X.S., Zhao, K., Chen, Q.J., Deng, F., Liu, L.L., Yan, B., Zhan, F.X., Wang, Y.Y., Xiao, G.F., Shi, Z.L., 2020. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270-273.

Acknowledgements

We thank Dr. Wilson, Mr. LaClair and Ms. Howard for their support throughout the study. We are grateful to Drs. Weir and Feigelstock for editing. The following reagent was deposited by the Centers for Diseases Control and Prevention and obtained through BEI Resources, NIAID, NIH: SARS-Related Coronavirus 2, Isolate USA-WA1/2020, NR-52281.

The authors declare no conflict of interest.

bioRxiv preprint doi: https://doi.org/10.1101/2020.04.29.067983; this version posted April 30, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.

Table 1. Evaluation of 19 investigational antiviral drugs against SARS-CoV-2 Infection

Drug Name	*Known antiviral mechanism*	*Multiplicity of Infection*		*IC_{50} (µM)*	*CC_{50} (µM)*	*SI*	*Concentrations tested (µM)*
		0.01	**0.001**				
Chloroquine pretreatment	antimalarials and amebicides	+	+	30	45	1.5	0.25,0.5,1,2,5,10,20,30,60,125,250,500
Chloroquine posttreatment	antimalarials and amebicides	±	±	>50	45	<0.9	0.25,0.5,1,2,5,10,20,30,60,125,250,500
Remdesivir	nucleotide prodrug	+	+	2.5	175	70	0.025, 0.05, 0.1, 0.2, 0.4, 0.8,1.5, 3.125, 6.25, 12.5,25, 50,100, 200
Sofosbuvir	HCV RdRP inhibitor	-	-	-	>200	-	0.01,0.1,0.5,1,2,5,10,50,100,150,200
Velpatasvir	HCV protease inhibitor	-	-	-	17	-	0.025, 0.05, 0.1, 0.2, 0.4, 0.8,1.6, 3.125, 6.25, 12.5,25, 50
Ledipasvir	HCV protease inhibitor	-	-	-	-	-	1, 10, 50
Sofosbuvir+Velpatasvir	HCV RdRP inhibitor + protease inhibitor	-	-	-	-	-	1, 10, 50
Sofosbuvir+Ledipasvir	HCV RdRP inhibitor + protease inhibitor	-	-	-	-	-	1, 10, 50
Danoprevir	HCV protease inhibitor	-	-	-	>50	-	0.025, 0.05, 0.09, 0.195, 0.39, 0.78,1.56, 3.125, 6.25, 12.5,25, 50
Nelfinavir	HIV protease inhibitor	-	-	-	-	-	1, 10, 50
Ritonavir	HIV protease inhibitor	-	-	-	-	-	1, 10, 50
Saquinavir	HIV protease inhibitor	-	-	-	-	-	1, 10, 50
Indinavir	HIV protease inhibitor	-	-	-	-	-	1, 10, 50
Amprenavir	HIV protease inhibitor	-	-	-	-	-	1, 10, 50
Lopinavir	HIV protease inhibitor	-	-	-	-	-	1, 10, 50
Raltegravir	HIV integrase inhibitor	-	-	-	-	-	1, 10, 50
Tenofovir	nucleotide analog reverse-transcriptase inhibitor	-	-	-	-	-	1, 10, 50
AZT	HIVs reverse transcriptase inhibitor	-	-	-	-	-	1, 10, 50
Favilavir	influenza RdRP inhibitor	-	-	-	-	-	1, 10, 50
Pocapavir	Poliovirus capsid inhibitor	-	-	-	12.5	-	0.025, 0.05, 0.1, 0.2, 0.4, 0.8,1.6, 3.125, 6.25, 12.5,25, 50
Bemcentinib (R428)	tyrosine kinase AXL inhibitor	-	±	-	-	-	1, 10, 50
Chloromethylketone	Furin convertase inhibitor	-	-	-	-	-	1, 10, 50

-, 0-10% protection; ±, 10-40% protection; +, >50% protection under at least one concentration that was tested. TI, therapeutic index (CC_{50}/ IC_{50}).